Engineered bacteria and bacterial derivatives as advanced therapeutics for inflammatory bowel disease
Essays in Biochemistry · 08.09.2025 · 69 (02) · 169-179
DOI: 10.1042/ebc20253003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Essays in Biochemistry, online erschienen am 27.02.2025. Verfasst von Jingyuan Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, P. R. China. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Probiotics, Bacteria. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inflammatory bowel disease (IBD), a chronic and relapsing-remitting condition, is inadequately managed by conventional therapies that often lack targeting specificity and carry significant side effects, particularly failing to address intestinal barrier repair and microbial balance. Probiotics, with their strong colonization capabilities, present a novel approach to drug delivery. Various engineering strategies have been developed to enhance the targeting ability of probiotics to inflammation sites, enabling precise delivery or in situ synthesis of therapeutic molecules to expand their multifunctional potential. This review discusses the recent advancements in bacterial modifications, including surface physico-chemical and biological coating, genetic engineering, outer membrane vesicles, minicells, and bacterial ghosts, all of which can enhance therapeutic localization. We also outline critical preclinical considerations, such as delivery frequency, systemic distribution, immune evasion, and gene contamination risks, for clinical translation. These engineered bacteria and bacterial derivatives hold great promise for personalized and sustained IBD treatments, providing a new frontier for therapy tailored to the complex inflammatory environment of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, P. R. China.
- NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, P.…
- The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Guangdong, 518172, P. R. China.
- Department of Chemistry, The Chinese University of Hong Kong, Shatin, N. T., Hong Kong, P. R. China.
ORCID-Profile: Zhaoting Li
Zitieren
APA
Wu, J., Ye, W., Yu, J., Zhou, T., Zhou, N., K P Ng, D., & Li, Z. (2025). Engineered bacteria and bacterial derivatives as advanced therapeutics for inflammatory bowel disease. Essays in Biochemistry, 69(02), 169-179. https://doi.org/10.1042/ebc20253003
Vancouver
Wu J, Ye W, Yu J, Zhou T, Zhou N, K P Ng D, et al. Engineered bacteria and bacterial derivatives as advanced therapeutics for inflammatory bowel disease. Essays in Biochemistry. 2025;69(02):169-179. doi:10.1042/ebc20253003
BibTeX
@article{Wu2025,
author = {Wu, Jingyuan and Ye, Wanlin and Yu, Jie and Zhou, Tuoyu and Zhou, Nuo and K P Ng, Dennis and Li, Zhaoting},
title = {Engineered bacteria and bacterial derivatives as advanced therapeutics for inflammatory bowel disease},
journal = {Essays in Biochemistry},
year = {2025},
volume = {69},
number = {02},
pages = {169--179},
doi = {10.1042/ebc20253003}
}
EUVIMED